Dr. John Leonard Discusses New Data from PYRAMID Study on Non-Germinal Center B-Cell-Like Subtype Diffuse Large Cell Lymphoma

In this video from the ASCO Post, Lymphoma Program Director, Dr. John Leonard discusses results presented at the 2015 meeting of the American Society of Hematology from the recently completed Pyramid trial.  This multi-center phase II study sought to determine whether R-CHOP was more effective with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma. (non-GCB DLBCL)

The study’s full abstract can be read here.

Dr. John Leonard Discusses the Top Lymphoma Studies from ASH15

In this video from Targeted Oncology, Lymphoma Program Director, Dr. John Leonard discusses the top lymphoma studies presented during the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

In addition to this video, Dr. Leonard also continued his now annual tradition of picking 10 noteworthy lymphoma abstracts released before the meeting in his #LeonardList. As he explained the criteria for picking abstracts on the list:

“I scan all the lymphoma-related abstracts, focusing less on the biology and more on the therapy. I look at both oral and poster abstracts because I think people might miss posters that are of interest and worth highlighting. And I focus on ideas I think are either practice changing, or intriguing, or ‘out of the box,’ that people might otherwise not see.”

 

Dr. John Leonard Describes Treatments Available to Patients with Indolent B-cell Non-Hodgkin Lymphoma

In this video from Onc Live, Lymphoma Program Director, Dr. John P. Leonard, describes treatment options available to patients with indolent B-cell non-Hodgkin lymphoma.

Current treatment options for NHL include single-agent rituximab, R-CHOP, and bendamustine plus rituximab. Although early data shows potential for lenalidomide alone or in combination with rituximab.

The variety of options available for patients with indolent B-cell non-Hodgkin lymphoma is due to extensive clinical trial testing. If you are interested in learning more information about the clinical trials available at Weill Cornell Medicine you can visit the Joint Clinical Trials website.